ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange. The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. Lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Lupuzor ™ has 'Gold Standard' approval from the US FDA for its Phase III trial with a Special Protocol Assessment and "Fast Track" designation. Lupuzor ™ has now commenced its Phase III pivotal trial.

TypePublic
HQLondon, GB
Size (employees)10 (est)
Websiteimmupharma.org
Immupharma is headquartered in London, GB
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Immupharma Office Locations

Immupharma has offices in London, Sarnen and Mulhouse
London, (HQ)
50 Broadway
Mulhouse,
5 Rue du Rhône
Sarnen,
10 Poststrasse
Show all (3)
Report incorrect company information

Immupharma Financials and Metrics

Immupharma Revenue

Immupharma's revenue was reported to be £150.46 k in FY, 2017
GBP

Revenue (FY, 2017)

150.5k

Net income (FY, 2017)

(6.2m)

EBITDA (FY, 2017)

(7.1m)

EBIT (FY, 2017)

(7.2m)

Cash (31-Dec-2017)

2.7m
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25.4k63.2k57.1k22.1m32.5k16.8k184.8k76.4k164.8k150.5k

Revenue growth, %

(59%)

Operating expense total

(1.5m)3.6m4.6m11.8m4.2m(3.8m)3.6m4.6m6.8m7.4m

EBITDA

(2.0m)(3.5m)(4.5m)10.3m(4.1m)3.9m(4.1m)(4.2m)(3.3m)(4.4m)(6.5m)(7.1m)
GBPFY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.01.01.0978.2k1.0m2.7m2.9m12.5m22.5m15.6m12.2m8.9m5.4m5.4m833.4k1.9m2.7m

Accounts Receivable

3.2k22.2k2.8k13.2k

Current Assets

1.01.01.0979.9k1.0m2.9m3.3m12.6m23.9m16.8m13.5m9.8m6.5m6.1m2.4m6.0m4.4m

PP&E

12.0k12.8k13.3k9.3k76.8k125.4k114.8k97.1k366.4k280.1k231.9k161.4k
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

1.4k15.1k(2.5m)(3.1m)4.7m8.1m(2.0m)(3.4m)(3.8m)(3.7m)(2.9m)(3.9m)(5.3m)(6.2m)

Cash From Operating Activities

15.8k18.3k879.6k3.8m(3.6m)12.0m(6.8m)(3.4m)(3.3m)(3.9m)(2.5m)(4.1m)(6.5m)(4.4m)

Cash From Financing Activities

977.0k3.0m(77.6k)12.0m(143.5k)555.2k165.3k356.9k191.5k3.0m(310.1k)7.4m5.4m

Net Change in Cash

978.2k27.1k2.7m3.7m8.5m11.9m(6.4m)(3.2m)(2.8m)(3.7m)199.0k(4.5m)896.3k945.9k
GBPY, 2017

Revenue/Employee

15.0k

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Immupharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Immupharma Blogs

Nominated Adviser Status

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser (“NOMAD”), Northland Capital Partners (“Northland”) with SP Angel Corporate Finance LLP. The Directors have also been inf…

Interim results announcement for the six months ended 30 June 2018

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2018 (the “Period”). Key Highlights Lupuzor Lupuzor™ demonstrated a superior response rate over placebo (52.5%…

Standford Capital Partners and Si Capital are appointed as joint broker

ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, is pleased to announce that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They will work in conjunction with Northland Capital Partners who are the Company’s NOMA…

IMM September 2018 Corporate Update

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company today announces a corporate update. Click here to view The post IMM September 2018 Corporate Update appeared first on ImmuPharma.

ImmuPharma announces positive pre-clinical data on its CIDP programme

Positive results of P140 (Lupuzor™ or Forigerimod) published in the Journal of Autoimmunity in a model of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The T cell modulator P140 significantly reduced the disease in the murine preclinical model Data provides evidence for the expansion of P…

Annual Report and Accounts Posted to Shareholders

Notice of Annual general Meeting on 28 June 2018 @ 10.30 AM Venue: Sky Light City Tower, 50 Basinghall Street, London, EC2 ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended …
Show more

Immupharma Company Life and Culture

Report incorrect company information

Immupharma Frequently Asked Questions

  • How many employees does Immupharma have?

    Immupharma has 10 employees.

  • What is Immupharma revenue?

    Latest Immupharma annual revenue is £150.5 k.

  • What is Immupharma revenue per employee?

    Latest Immupharma revenue per employee is £15 k.

  • Who are Immupharma competitors?

    Competitors of Immupharma include myTomorrows, Actinium Pharmaceuticals and MWI Veterinary Supply.

  • Where is Immupharma headquarters?

    Immupharma headquarters is located at 50 Broadway, London.

  • Where are Immupharma offices?

    Immupharma has offices in London, Sarnen and Mulhouse.

  • How many offices does Immupharma have?

    Immupharma has 3 offices.